Abate Kristin
Abate Kristin, CAO, reported an open-market or private sale at Karyopharm Therapeutics Inc. involving 4788.000000 shares for an estimated $1647.07. Reported holdings after the transaction were 18616.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Oct 16, 2026
- Filing date
- Oct 19, 2026
How reported position traded is calculated
Shares sold ÷ (holdings after + shares sold). Estimated position before: 23,404 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
KPTI price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- Sell Code S
- Identifier
- 0001193125-26-425227 Common Stock
- Transaction date
- Oct 16, 2026 Filed Oct 19, 2026, 08:03 PM · 3d delay
- Shares
- 4,788 sh $0.34 per share
- Estimated value
- -$1.64k Computed from shares × price
- Holdings after
- 18,616 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
+6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Accounting Officer
- F1
This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the paym…
0 other transactions
0 recent txs